News Home

Should You Buy Horizon Therapeutics PLC (HZNP) Stock After it Has Gained 3.54% in a Week?

Wednesday, October 05, 2022 10:36 AM | InvestorsObserver Analysts
Should You Buy Horizon Therapeutics PLC (HZNP) Stock After it Has Gained 3.54% in a Week?

Overall market sentiment has been high on Horizon Therapeutics PLC (HZNP) stock lately. HZNP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Horizon Therapeutics PLC has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on HZNP!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With HZNP Stock Today?

Horizon Therapeutics PLC (HZNP) stock is trading at $66.10 as of 10:36 AM on Wednesday, Oct 5, a loss of -$0.07, or -0.1% from the previous closing price of $66.16. Volume today is light. So far 709,599 shares have traded compared to average volume of 2,567,005 shares. The stock has traded between $65.55 and $67.64 so far today.

More About Horizon Therapeutics PLC

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States. Click Here to get the full Stock Report for Horizon Therapeutics PLC stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App